A Phase IIb Study of NeuroVax, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis Slowing Disease Progression Via Vaccination

Trial Profile

A Phase IIb Study of NeuroVax, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis Slowing Disease Progression Via Vaccination

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Feb 2016

At a glance

  • Drugs IR 902 (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Sponsors Immune Response BioPharma
  • Most Recent Events

    • 22 Feb 2016 Planned End Date changed from 1 Mar 2018 to 1 Mar 2019, according to ClinicalTrials.gov record.
    • 22 Feb 2016 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2019, according to ClinicalTrials.gov record.
    • 22 Feb 2016 Planned initiation date changed from 1 Mar 2016 to 1 Mar 2017, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top